company background image
6JU0 logo

BioCardia DB:6JU0 Stock Report

Last Price

€4.78

Market Cap

€5.3m

7D

0%

1Y

-56.0%

Updated

27 Aug, 2024

Data

Company Financials +

6JU0 Stock Overview

A clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. More details

6JU0 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

BioCardia, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioCardia
Historical stock prices
Current Share PriceUS$4.78
52 Week HighUS$18.45
52 Week LowUS$0.15
Beta1.36
11 Month Change0%
3 Month Change12.24%
1 Year Change-56.03%
33 Year Change-86.99%
5 Year Changen/a
Change since IPO-81.14%

Recent News & Updates

Recent updates

Shareholder Returns

6JU0DE BiotechsDE Market
7D0%-0.7%-0.02%
1Y-56.0%-17.2%8.2%

Return vs Industry: 6JU0 underperformed the German Biotechs industry which returned -19.7% over the past year.

Return vs Market: 6JU0 underperformed the German Market which returned 4.9% over the past year.

Price Volatility

Is 6JU0's price volatile compared to industry and market?
6JU0 volatility
6JU0 Average Weekly Movementn/a
Biotechs Industry Average Movement6.4%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.9%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 6JU0 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 6JU0's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a18Peter Altmanwww.biocardia.com

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome.

BioCardia, Inc. Fundamentals Summary

How do BioCardia's earnings and revenue compare to its market cap?
6JU0 fundamental statistics
Market cap€5.27m
Earnings (TTM)-€7.66m
Revenue (TTM)€383.23k

13.7x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6JU0 income statement (TTM)
RevenueUS$428.00k
Cost of RevenueUS$5.07m
Gross Profit-US$4.64m
Other ExpensesUS$3.92m
Earnings-US$8.56m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-4.03
Gross Margin-1,084.35%
Net Profit Margin-1,999.77%
Debt/Equity Ratio0%

How did 6JU0 perform over the long term?

See historical performance and comparison